Filing Flows › Co-Diagnostics (CODX) › Q1 2026
Co-Diagnostics (CODX) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Co-Diagnostics (CODX) reported revenue of $146K for the first quarter 2026 (Q1 2026), +190% from a year earlier and -45% from the quarter before.
Co-Diagnostics, Q1 2026: revenue $146K (+190% year over year), net loss $9.1M, operating cash flow −$7.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $146K | -45% | +190% |
| Operating profit | −$9.2M | — | — |
| Net earnings | −$9.1M | — | — |
| Operating cash flow | −$7.8M | — | — |
What changed
Revenue was $146K in Q1 2026, up 190% year over year and down 45% from the previous quarter.
Operating costs exceeded revenue by $9.2M, an operating margin of -6309.1%. The fastest-growing cost line was Research & development (+22%). The quarter ended with a net loss of $9.1M, narrower than the previous quarter's $25.7M loss.
Operating cash flow was −$7.8M. Non-cash charges added back $255K of depreciation and amortization and $219K of share-based compensation. Working capital and other items added $819K. Capital expenditures of $142K exceeded it, leaving free cash flow of −$8.0M.
Questions
What was Co-Diagnostics' revenue in the first quarter 2026?
Co-Diagnostics (CODX) reported revenue of $146K for the first quarter 2026 (Q1 2026), +190% from a year earlier and -45% from the quarter before.
Source: Co-Diagnostics 10-Q on SEC EDGAR.